
    
      Patients with advanced NSCLC, colorectal cancer, and head and neck cancer that progressed
      after at least 1 prior regimen for metastatic disease were eligible. Wild-type K-ras was
      required in colon cancer. All patients received cetuximab 400 mg/m2 week 1 followed by 250
      mg/m2/week. Four dose levels of ridaforolimus were planned: 10mg, 20mg, 30mg, and 40mg daily,
      5 days each week, on a 28-day cycle.
    
  